The objective of this study was to evaluate the short-term and long-term outcomes of adult patients with hematologic malignancies who received chemotherapy in the intensive care unit (ICU). METHODS: This was a retrospective, single-center study comparing the outcomes of patients with hematologic malignancies who received chemotherapy in the ICU with a matched cohort of ICU patients who did not receive chemotherapy. Conditional logistic regression and shared-frailty Cox regression were used to assess short-term (ICU and hospital) mortality and death by 12 months after hospital discharge, respectively. RESULTS: One hundred eightyone patients with hematologic malignancies received chemotherapy in the ICU. The ICU and hospital mortality rates were 25% and 42% for chemotherapy patients and 22% and 33% for non-chemotherapy patients, respectively. Higher severity of illness scores on ICU admission were significantly associated with higher ICU mortality (odds ratio, 1.07; P <.001) and hospital mortality (odds ratio, 1.05; P .001). Six-month and 12-month survival estimates posthospital discharge were 58% and 50%, respectively. Compared with the matched cohort of patients who did not receive chemotherapy, those who did receive chemotherapy had a significantly longer length of stay in the ICU (median, 6 vs 3 days; P <.001) and in the hospital (median, 22 vs 14 days; P 5.024). In multivariable analysis, the patients who received chemotherapy in the ICU had a trend toward a higher risk of dying by 12 months (hazard ratio, 1.45; P 5.08). CONCLUSIONS: Short-term mortality was similar among patients with hematologic malignancies who did and did not receive chemotherapy in the ICU, although patients who received chemotherapy had increased resource utilization. These results may inform ICU triage and goals-of-care discussions with patients and their families regarding outcomes after receiving chemotherapy in the ICU. Cancer 2018;124:3025-36.
INTRODUCTION
A complex host of factors influences the decision to administer oncologic therapies in the intensive care unit (ICU) to patients with hematologic malignancies. These include the improved short-term (ICU and hospital) and long-term (posthospital discharge) survival rates associated with this patient cohort [1] [2] [3] ; the type and status of the underlying malignancy; concerns about potential adverse effects because of oncologic therapies; and the presence of life-threatening, critical illness syndromes. Other important considerations include the capabilities of the ICU to support active treatment of oncologic patients and the negative biases of the ICU toward patients with a perceived poor outcome because of their cancer or need for oncologic therapies.
Although the prognostic factors and outcomes in patients with hematologic malignancies who are admitted to oncologic ICUs have been extensively examined, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] only 4 studies (3 retrospective and 1 prospective) have specifically addressed the outcomes of patients receiving chemotherapy in the ICU. [4] [5] [6] [7] All 4 studies were based in oncologic ICUs at single centers outside the United States, were retrospective in design, had relatively small numbers of patients (<100 patients with hematologic malignancies), and (except for 1 study 7 ) reported only short-term outcomes (<6 months). Notably, these studies [4] [5] [6] [7] focused on patients receiving initiation chemotherapy for newly diagnosed hematologic malignancies and did not address the clinical factors or outcomes of those receiving continuation chemotherapy.
The objective of the current study was to improve our understanding of the characteristics and outcomes of patients with hematologic malignancies who receive chemotherapy in the ICU. Our goals were to describe reasons for ICU admission, the timing and types of chemotherapy regimens received, whether the regimens were initial treatment or part of ongoing oncologic treatment, and both short-term (ICU and hospital mortality) and long-term (death by 12 months) outcomes. We also compared the outcomes of these patients with outcomes in a cohort of matched patients who had similar hematologic malignancies and were admitted to the ICU during the same period but did not receive chemotherapy.
MATERIALS AND METHODS
This retrospective study was conducted between January 1, 2010, and December 31, 2015 , in the 20-bed, adult ICU of Memorial Sloan Kettering Cancer Center. The ICU is staffed by intensivist-led multidisciplinary teams, and all patients are cared for in collaboration with the patient's primary oncologist or surgeon. All consultations for ICU admission are triaged through the admitting intensivist attending physicians. Patients are admitted primarily with 1 or more organ dysfunction(s) and for lifeextending therapeutic options associated with potentially severe adverse effects.
The decision to administer chemotherapy in the ICU is jointly agreed upon by oncologists and intensivists after discussions with the patients and/or their authorized representatives. These medications are solely prescribed by oncologists and prepared by specialty pharmacists. Intravenous agents are administered by chemotherapy nurses; in contrast, oral agents are administered by ICU nurses. In this study, we define chemotherapy as any combination of traditional cytotoxic chemotherapy, biologic therapy, or immune therapy directed at a hematologic malignancy. Radiation therapy alone was not considered. A waiver of authorization for this study was obtained through our Institutional Review Board.
Data Sources
By using hospital-wide and ICU databases, we identified all ICU patients with hematologic malignancies who received chemotherapy in the ICU. We included for analysis only the first ICU admission during which the patient received chemotherapy; subsequent ICU admissions for chemotherapy were excluded. We also excluded patients who received chemotherapeutic agents as part of the conditioning regimen for autologous or allogeneic hematopoietic stem cell transplantation (HSCT); administered concomitantly with major surgical procedures; instilled in body cavities to facilitate sclerosis (ie, pericardial and pleural spaces); or given for noncancerous conditions (eg, autoimmune or viral diseases). Similarly, patients who received only corticosteroids also were excluded because of the extensive use of many types of corticosteroids for numerous conditions in our ICU.
Demographics and outcomes
Demographic and clinical data included age; sex; severity of illness score using the Mortality Probability Model at ICU Admission, version 2 (MPM-II); history of HSCT; primary ICU admission diagnosis, as noted in the admission day critical care attending physician note; Charlson comorbidity index 15 ; dates of hospital and ICU admissions; Sequential Organ Failure Assessment (SOFA) score at the start of chemotherapy; use of mechanical ventilation, vasopressor medications, and renal replacement therapies (hemodialysis or continuous renal replacement therapy) on admission and during ICU stay; and ICU and hospital length of stay (LOS). Primary outcomes were ICU and hospital mortality and survival by 12 months after hospital discharge.
Cancer diagnoses and chemotherapy
Hematologic malignancies were classified as newly diagnosed (within 30 days of ICU admission) or later diagnosed (>30 days; includes relapse/progression). We coded chemotherapy as initiation (initial administration) or continuation (part of an ongoing regimen). Patients who received their first chemotherapy within 5 days before ICU admission with carry-over into the ICU were also included in the initiation category.
Chemotherapy data collected included the ICU start date, type (cytotoxic, biologic or immune), number (single or multiple), and route of administration (parenteral, oral, intrathecal, or subcutaneous). We also determined the date of the original cancer diagnosis and the last date patients received chemotherapy before ICU admission for the continuation group.
Statistical Analysis
Patients who received chemotherapy were individually matched 1:1 to nonchemotherapy patients on age, sex (men and women), and disease type (leukemia and lymphoma). Exact matches were used for sex and disease type, whereas a 0.25-caliper match was used for age, and a greedy-match algorithm was used. Patients who were not matched were dropped from the analyses. Characteristics between patients who did and did not receive chemotherapy were compared Original Article using the McNemar test and the Wilcoxon signed-rank test, as appropriate.
We assessed 3 outcomes: death in ICU, death in hospital, and death by 12-months posthospital discharge. Death in ICU and death in hospital were treated as binary covariates. 16 Correlations between covariates and shortterm outcomes were assessed with univariable and multivariable conditional logistic regression with matched-pair serving as strata. All factors were adjusted for in multivariable models regardless of significance; however, because the MPM-II score on ICU admission incorporates the need for mechanical ventilation and vasopressor agents, only the MPM-II score was included in multivariable models. Death by 12 months was assessed from the time of hospital discharge until death. Patients who remained alive at 12 months were censored. Only patients who were alive at hospital discharge were included in this analysis. Kaplan-Meier methods were used to estimate survival, and univariable and multivariable shared-frailty Cox regressions were used to assess the relation between covariates and death by 12 months. The proportional-hazards assumption was assessed through residual plots.
To analyze the effect of initiation versus continuation chemotherapy on ICU and hospital mortality and survival by 12 months in the chemotherapy cohort, standard logistic regression and Cox proportional-hazards regression were used. The Fisher exact test and the Wilcoxon rank-sum test were used to check for differences between the initiation and continuation chemotherapy groups. Two-sided P values .05 were considered statistically significant. All analyses were performed with the SAS statistical software package (version 9.4; SAS Institute Inc, Cary, NC).
RESULTS
During the study period, 4973 patients were admitted to the ICU. Of these, 186 patients (3.7%) with hematologic malignancies received chemotherapy in the ICU (Fig. 1) . Of the 186 patients, 181 were successfully matched to ICU patients who did not receive chemotherapy ( Table   TABLE 2 Patients who received chemotherapy in the ICU (n 5 181) were primarily men (n 5 115 patients; 64%) with a median age of 62 years (range, 18-86 years) ( Table  1) . One hundred three patients (57%) were treated for lymphoma, and 78 (43%) were treated for leukemia. Sixty-nine patients (38%) were treated for newly diagnosed hematologic malignancies. Twenty patients (11%) underwent prior HSCT, and 2 patients (1%) received radiation therapy during their ICU stay. Primary ICU admitting diagnoses were sepsis/septic shock (n 5 47; 27%), chemotherapy administration (n 5 45; 25%), respiratory insufficiency/failure (n 5 33; 19%), renal insufficiency/failure (n 5 23; 13%), and bleeding (n 5 11; 6%) ( Cytotoxic chemotherapy agents were received by 135 patients (75%), immunotherapy agents were received by 21 patients (12%), and combined regimens were received by 25 patients (14%). One hundred three patients (57%) received multiple agents. The median time between the diagnosis of cancer and ICU admission was 5 months (range, 0-318 months). Sixty-eight patients (38%) were diagnosed with cancer within 30 days of ICU admission. Fifty-six patients (31%) received chemotherapy within 5 days of ICU admission, 33 patients (18%) received chemotherapy 5-30 days before admission, and 92 patients (51%) did not receive chemotherapy within 30 days of ICU admission. Seventy-two patients (40%) received initiation therapies and 109 patients (60%) received continuation therapies in the ICU (Table 2) . Of the 56 patients who received chemotherapy within 5 days, only 8 (14%) were from the initiation cohort. In those patients who received chemotherapy after ICU admission, the median time was 1.5 days overall (range, 1-17 days), with a median of 1 day (range, 1-16 days) for patients in the continuation group and 2 days (range, 1-17 days) in the initiation group. Table 3 ). In addition, higher MPM-II scores on ICU admission were associated with a higher risk of ICU mortality (OR, 1.07; 95% CI, 1.03-1.10; P < .001) and hospital mortality (OR:1.05; 95% CI, 1.03-1.07; P < .001) ( Table 2 ).
Posthospital survival outcomes
Of the 362 patients, 227 (63%) were discharged alive, including 105 from the chemotherapy cohort and 122 from the nonchemotherapy cohort. At 6 months, the estimated survival was 58% (95% CI, 48%-67%) for patients in the chemotherapy cohort and 73% (95% CI, 64%-80%) for those in the nonchemotherapy cohort. At 12 months, the estimated survival was 50% (95% CI, 40%-59%) in the chemotherapy cohort and 59% (95% CI, 50%-67%) in the nonchemotherapy cohort (Fig. 2) . Patients who received chemotherapy demonstrated a lower survival distribution compared with those who did not receive chemotherapy (Supporting Fig. 1 ). Furthermore, in multivariable analyses, patients who received chemotherapy in the ICU had a trend toward a higher risk of dying by 12 months (OR, 1.45; 95% CI, 0.95-2.19; P 5 .08) ( Table 4 ). In contrast to ICU and hospital mortality, the MPM-II score on ICU admission was not significantly associated with death by 12 months (P 5 .14) ( Table 3) .
Initiation Versus Continuation Chemotherapy Patients
The proportion of patients with a history of HSCT was greater (18 of 109 patients; 17%) among patients in the continuation chemotherapy group compared with those in the initiation chemotherapy group (2 of 72 patients; 3%) (P 5 .003). In addition, patients in the initiation group were more likely to be newly diagnosed (67 of 72 patients; 93%) compared with those in the continuation group (2 of 109 patients; 2%; P < .001) ( Table 2) . No other significant differences were observed between the initiation and continuation groups (P 5 .12 to > .95).
ICU and hospital mortality
ICU mortality was 28% (31 of 109 patients) in the continuation group and 21% (15 of 72 patients) in the initiation group. In multivariable analyses, no significant differences in ICU mortality were observed between the continuation and initiation chemotherapy groups (P 5 .27) (Supporting Table 1 ). Overall hospital mortality was 48% (52 of 109 patient) in the continuation group and 33% (24 of 72 patients) in the initiation group. Although patients who received continuation chemotherapy had a trend toward higher odds of hospital mortality than those in the initiation group on univariable analyses (OR, 1.82; 95% CI, 0.98-3.38; P 5 .056), no significant difference in hospital mortality was observed between patients in the initiation and continuation therapy groups after adjusting for known mortality predictors (OR, 1.80; 95% CI, 0.89-3.64; P 5 .10) (Supporting Table 2 ).
Posthospital survival outcomes
At 12 months, estimated survival was 42% (95% CI, 29%-54%) in the continuation group and 58% (95% CI, 43%-71%) in the initiation group (Supporting Fig. 2 ). In multivariable analyses, patients who received continuation chemotherapy had a significantly higher risk of death by 12 months (hazard ratio, 1.77; 95% CI, 1.21-2.60; P 5 .003) than those who received initiation chemotherapy (Supporting Table 2 ).
DISCUSSION
This is the first and largest study to date of patients with hematologic malignancies who received chemotherapy in the ICU at a US tertiary cancer center. Moreover, to our knowledge, we are the first to describe the short-term and long-term outcomes of patients who received initiation or continuation chemotherapy in the ICU.
The main findings of our study are that patients with hematologic malignancies who receive chemotherapy in the ICU did not have differences in short-term mortality outcomes but did have significantly longer ICU and hospital LOS and a higher risk of death by 12 months than matched patients who did not receive chemotherapy. There were no significant differences in ICU mortality between the initiation and continuation chemotherapy groups. The trend toward higher odds of hospital mortality among patients who received continuation chemotherapy may reflect their underlying disease severity.
Our ICU and hospital mortality rates of 25% and 42%, respectively, for the chemotherapy cohort are comparable to the reported 25% to 40% and 41% to 43% ICU and hospital mortality rates, respectively, in 4 previous studies of patients who received chemotherapy in the ICU. [4] [5] [6] [7] We also observed that the severity of illness score (MPM-II) on ICU admission was associated significantly with worse short-term outcomes. Three of the 4 prior studies reported the severity of illness score (ie, Simplified Acute Physiology Score II) as strongly associated with short-term outcomes. 4, 6, 7 Studies of critically ill patients with cancer consistently have demonstrated that shortterm survival is primarily determined by the extent of organ failures at ICU admission, particularly the need for mechanical ventilation and vasopressors. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In our chemotherapy cohort, 38% and 34% of patients required mechanical ventilation and vasopressors, respectively. We were unable to establish a precise reason why, despite a lower MPM scored on ICU admission, patients in the chemotherapy group had higher in-hospital mortality (although the difference was nonstatistically significant). We can only speculate that some patients who received chemotherapy in the ICU already were receiving thirdline or fourth-line regimens; and, although they survived the ICU admission, they were more likely to have been designated as do not resuscitate on ICU discharge; more likely not return to the ICU; and, because of the nature of their malignancy, had higher hospital mortality. For analysis only, we also included the first ICU admission during which the patient received chemotherapy. Readmissions of patients who had previously received chemotherapy in the ICU were not analyzed.
We also observed that patients who had a same-day hospital and ICU admission had lower odds of ICU and hospital mortality, possibly related to their pre-emptive ICU admission in anticipation of possible deterioration. A small, retrospective, single-center study demonstrated that direct admission to the ICU of patients with highrisk acute myelogenous leukemia who were receiving chemotherapy and had physiologic disturbances (but no organ dysfunction) was associated with improved outcomes. 29 Only 1 previous study analyzed long-term survival of patients with cancer who received chemotherapy in the ICU. 7 That analysis involved 56 patients with cancer (87.5% had hematologic malignancies) and reported survival rates of 49% and 41% at 6 and 12 months, respectively, which were lower than the 66% and 55% survival rates in our chemotherapy cohort (Supporting Fig. 1 ). Their survival may have been lower for a few reasons related to sample selection and treatment. First, our patients may have been less sick at ICU admission, thus positively impacting their long-term survival. 30 Second, it is possible that our cancer center offers superior posthospital oncologic care and therapies. Finally, there were underlying differences in study sample selection (ie, inclusion of solid and hematologic malignancies in the earlier study).
Our current findings may offer guidance for the triage of patients with cancer who are being considered for ICU admission. Recent literature demonstrates that oncologic patients with critical illness have improved outcomes, 1-3 thus encouraging their admission to the ICU. However, recent national society guidelines 31 do not specifically address the triage question of admitting patients with cancer for therapeutic processes such as chemotherapy. In our study, we observed that this specific group of oncologic patients admitted for chemotherapy had outcomes equal to those in the matched group. This suggests that outcomes alone should not affect triage or the administration of chemotherapy. However, we also observed that the patients who received chemotherapy had a significantly longer ICU and hospital LOS than patients who did not. The correlation between the duration of chemotherapy in the ICU and ICU LOS was weak to moderate (q 5 0.28; P 5 .001), so treatment alone did not fully explain the difference in LOS. This increase in resource use certainly may play a role in triage and therapeutic decisions when ICU beds are severely limited or within noncancer hospitals that do not specialize in oncologic therapeutic administration in the ICU.
A major strength of our study is the comparison with a matched cohort of ICU patients with similar malignancies who did not receive chemotherapy. This allowed us to control for the influence of 3 possible confounding factors (age, sex, and type of malignancy) on the outcomes of patients with hematologic malignancies who received chemotherapy in the ICU. First, we demonstrated that, in contrast to the patients who did not receive chemotherapy in the ICU, those who did receive chemotherapy were more likely to have a longer ICU and hospital LOS, a greater need for mechanical ventilation (during ICU stay), and a higher risk of death by 12 months. Our findings also reinforce the crucial role of understanding the capabilities and the triage approaches of the ICU to support these seriously ill patients.
Our study has several limitations. First, despite the large number of patients and analyses of prospectively collected clinical data, the study was retrospective and observational in nature and was conducted at a single center with an ICU staff that is dedicated to supporting oncologic therapies. This is a similar limitation to the previous studies, [4] [5] [6] [7] which also were performed in specialized oncologic ICUs. Second, it is possible that there was selection bias in the triage of patients admitted to the ICU for chemotherapy. However, even among oncologists and intensivists, there is variation in ICU triage of patients who have cancer with favorable and unfavorable prognoses, 32 which may compensate for this limitation. Third, although it was obvious why chemotherapy was given in the initiation group, it was not possible for us to determine the reasons why chemotherapy was administered (compassionate/end-of-life, heroic, others) in the continuation group. Finally, we did not collect quality-of-life outcomes, including functional status and the ability to receive continued oncologic treatment after ICU discharge.
In conclusion, the current study demonstrated that there were no differences in short-term mortality among patients with hematologic malignancies who did or did not receive chemotherapy in the ICU. However, patients who received chemotherapy had increased ICU and hospital resource use and a marginally higher risk of death by 12 months. The severity of illness score on ICU admission was significantly associated with ICU and hospital mortality and death at 12 months. These data can assist oncology and critical care teams when discussing goals of care and prognosticating outcomes of patients who receive
